Revance Therapeutics — Investor Day (September 2023)
112 slides from Revance Therapeutics's investor day presentation, Sep 19, 2023
Slide 1: Investor Day 2023
Exhibit 99.2 INVESTOR DAY 2023 The presentations today contain information about Revance’s business for stockholders, potential investors, and financial analysts. The content shared is intended for this audience only.
Slide 2: Welcome
INVESTOR DAY 2023 WELCOME MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience
Slide 3: Program
INVESTOR DAY 2023 PR O GR A M REVANCE AESTHETICS DAXXIFY® KOL PANEL B R E AK REVANCE THERAPEUTICS Speakers: FUTURE GROWTH OPPORTUNITIES Mark J. Foley - Chief Executive Officer Dustin S. Sjuts – President FINANCIAL REVIEW Tobin C. Schilke – Chief Financial Officer CLOSING REMARKS David A. Hollander,
Slide 4: Forward-Looking Statements
Forward-Looking Statement Forward-Looking Statements Any statements in this presentation that are not statements of historical fact, including statements related to our 2023 guidance and guidance plans; our adjusted gross margins; our funding to cash flow breakeven; our capital requirements; the tim
Slide 5: We seek to disrupt large, established, growing markets in aesthetics and therapeutics
We seek to disrupt large, established, and growing markets in aesthetics and therapeutics through innovation 5 Intended for investor audience
Slide 6: DAXXIFY anchors our portfolio
® DAXXIFY anchors our portfolio st 1 true innovation in neuromodulator formulation in >30 years Pipeline in a product totaling $5B U.S. market 1 opportunity 1. Market size as of 2022. Data on file. Decision Resources Group Therapeutic Botulinum Toxin Market Analysis Global, 2023. Intended for invest
Slide 7: Our journey is rooted in >20 years of R&D
Our journey is rooted in >20 years of R&D $302M Cumulative Product Revenue (Q2’23) 2020 - Today 2002 2007 2012-2021 2018-2020 Commercialization Injectable Topical Strategic Peptides + Botulinum Toxin Botulinum Partnerships Biologics RHA® Collection Teoxane SA Clinical Toxin Program Clinical Work + V
Slide 8: We have a clear strategy to execute our vision
We have a clear strategy to execute our vision Intended for investor audience
Slide 9: Provider-centric growth pipeline
PR OVI D E R - CE N T R I C GROWTH PIPELINE I N N OVA T IVE S TRATE GY PR OD U CT S ® Leverage DAXXIFY Execute provider-centric Aesthetics, Therapeutics, ® and RHA Collection commercial strategy to International Expansion, to underpin growth maximize portfolio value Partnerships, Supply Chain Intend
Slide 10: Roadmap to unlocking our blockbuster opportunity
With a roadmap to unlocking our blockbuster opportunity in U.S. aesthetics and beyond Intended for investor audience
Slide 11: 2023, 2024 and Beyond milestones
2023 2024 Beyond ® • DAXXIFY cervical dystonia • Contract manufacturer addition ® DAXXIFY commercial launch launch ® • DAXXIFY international expansion ® Continued growth of RHA fillers • Anticipated approvals in aesthetics and therapeutics • Therapeutic pipeline expansion ® FDA approval – DAXXIFY in
Slide 12: Revance Aesthetics
INVESTOR DAY 2023 REVANCE AESTHETICS Intended for investor audience
Slide 13: Agenda
A GEND A U.S. Facial Injectables Landscape ® DAXXIFY Overview, Launch Progress and Update ® RHA Collection Overview, Launch Progress and Update Loyalty and Practice Partnership ® DAXXIFY KOL Panel Intended for investor audience
Slide 14: U.S. Facial Injectables Landscape
U.S. FACIAL INJECTABLES LANDSCAPE Intended for investor audience
Slide 15: The U.S. facial injectables market is robust and attractive
The U.S. facial injectables market is robust and attractive 2 Market penetrated <10% $2.5B N EUR O MO D UL A T O R S 1 0. 6 % CA GR Cash pay, high margins #1, #2 most performed minimally $3.9B 3 invasive cosmetic procedures 1 US MARKET OPPORTUNITY 9.5% CAGR Strong historic and forward CAGR >8% $1.4B
Slide 16: Aesthetic treatments are resilient: survey results
SURVEY QUESTION : If you had to reduce overall spending, what are the three areas you are most likely to cut back on? Nail care 51.4% Aesthetic Clothing 49.7% treatments are Spa/massage 47.3% resilient; only 25% Fitness/ gym membership 38.5% of consumers Travel 30.7% would cut back if Cosmetics 29.5
Slide 17: Three pillars to compete effectively in facial injectables
Three pillars to compete effectively in the facial injectables market: N E U R OM OD U L ATOR F I LLER EN G A G EME N T Loyalty & Practice Partnership + + Intended for investor audience
Slide 18: DAXXIFY Overview, Launch Progress & Update
® DAXXIFY OVERVIEW, LAUNCH PROGRESS & UPDATE Intended for investor audience
Slide 19: The DAXXIFY Difference
® THE DAXXIFY DIFFERENCE Intended for investor audience
Slide 20: First and only peptide formulated, long-lasting neuromodulator
st 1 and only peptide formulated, long-lasting neuromodulator Innovation foundation—proprietary TM Peptide Exchange Technology (PXT) Advantages of stabilizing BoNT/A with PXT: 1,2 • Prevents adsorption and aggregation of BoNT/A 3* • Enhances BoNT/A affinity for cell membranes 4 Proprietary, syntheti
Slide 21: Duration is the most important factor for consumers
SURVEY QUESTION : On a scale from 1 to 5, how important are these factors when deciding which neurotoxin to use? #1 Duration continues to be the most important factor for consumers when deciding which neuromodulator to use Source: The State of Aesthetics – Summer 2023 by the Numbers, Beauty Engine A
Slide 22: How is DAXXIFY different?
® How is DAXXIFY different? ® Botox ® 1 ®3 ®4 ®5 DAXXIFY Dysport Xeomin Jeuveau 2 Cosmetic Molecular weight 150 kDa 900 kDa ~400 kDa 150 kDa 900 kDa Glabellar line dose 40U 20U 50U 20U 20U 6 6 6 7 Core active ingredient (ng) 0.18 ng 0.18 ng 0.27 ng 0.08 ng 0.12 ng ✓ Peptide excipient formulation No
Slide 23: Differentiated duration profile across clinical programs
® The differentiated duration profile of DAXXIFY is demonstrated across clinical programs in aesthetics and therapeutics A ESTH ETI C S TH ER A P U ET I C S 20-24 weeks 24 weeks Median duration Median duration SAKURA pivotal trials and OLS – largest ASPEN-1 Phase 3 pivotal trial and OLS for Phase 3
Slide 24: Launch Highlights
Launch Solid Encouraging Executing on Highlights Commercial Real-World Opportunities Progress Learnings to Maximize on Product to Launch Performance Intended for investor audience
Slide 25: DAXXIFY Commercial Timeline
® DAXXIFY Commercial Timeline Measured launch strategy was designed to inform optimal market positioning SALES FORCE EXPANSION & RAMP Sept 2022 Sept 2022 Dec 2022 Mar 2023 Now PrevU U.S. FDA PrevU FACULTY TARGETED 1 year approval PROGRAM APPROVAL TRAINING COMMERCIAL anniversary (~400 accounts) LAUNC
Slide 26: First launch year sales by brand
ST 1 1 LAUNCH YEAR SALES BY BRAND ( $M ) $25 $49M $20 Most successful neuromodulator $15 ® launch since Botox $10 1 Cosmetic $5 $0 Launch Qtr 1 Launch Qtr 2 Launch Qtr 3 Launch Qtr 4 ® ® ® ® Dysport Xeomin Jeuveau DAXXIFY 1. Based on Q4’22 to Q2’23 DAXXIFY sales and first year launch sales of Dyspor
Slide 27: HCP share and patient conversion to DAXXIFY
% SHARE D A XXI FY® ® P RE - D A X X I FY % SHARE TAKE L AU N C H (Past 3 Months) ® Botox Cosmetic HCPs have converted 51% 8% 16% of their patients to ® Dysport 28% 4% ® DAXXIFY , the majority ® coming from the Jeuveau 12% 2% leading competitor ® Xeomin 9% 2% 1-4 Brand split in past 3 months compare
Slide 28: Encouraging Real-World Learnings
Encouraging Real-World Learnings Intended for investor audience
Slide 29: Satisfaction from HCPs and patients
S ATI S F AC T I O N from Respondents >4 out of 5 HCPs and 82% of HCPs are satisfied or very satisfied patients are satisfied ®1 with the results of DAXXIFY or very satisfied with the aesthetic results 84% ® ® of DAXXIFY patients are satisfied or from DAXXIFY 2 very satisfied with their results Base
Slide 30: Real-world duration consistent with clinical trial data
® Real-world feedback on the duration of DAXXIFY is consistent with our clinical trial data None or Mild Response Rates on 4-Point Investigator Assessment Over Time SAKURA 3 Cycle 1 (n=2380 treatments) 98 100 96 95 SAKURA 3 Cycle 2 (n=882 treatments) 88 88 90 86 90 86 SAKURA 3 Cycle 3 (n=568 treatme
Slide 31: HCPs inject DAXXIFY in each treatment area
® 1 % of HCPs who inject DAXXIFY in each treatment area GLABELLAR LINES FOREHEAD LINES 98% 98% ® DAXXIFY is used UNDER THE EYES LATERAL BROW 40% 84% broadly across NOSE CROW’S FEET 72% 97% UPPER LIP LINE the face GUMMY SMILE 57% 33% MARIONETTE LINES JAWLINE 43% 43% CHIN NECK 57% 50% 1 Over the past
Slide 32: Fast onset and improved skin smoothness
FAST TREATMENT ONSET IMPROVED SKIN SMOOTHNESS Based on patient diary data from SAKURA 1 and 2 pivotal trials A quantitative image analysis demonstrated improved skin smoothness in patients who have been treated with ® 1 DAXXIFY in glabellar lines 90% of patients achieved improvement in skin texture
Slide 33: Top reasons HCPs prefer DAXXIFY
® Top 3 reasons why HCPs prefer DAXXIFY over first-choice short-acting toxin Duration of effect 73% “DAXXIFY works faster, lasts longer, skin looks Quick onset of effect 70% better.” Aesthetic Physician Private Practice Skin quality 55% ® % of HCPs who rank DAXXIFY “Superior” to first-choice 1 short
Slide 34: Additional observations
ADDITIONAL OBSERVATIONS… • Straight-forward reconstitution • Similar glabellar lines injection technique • Importance of proper dosing • No human serum albumin (HSA) or animal proteins and U.S.-based manufacturing Intended for investor audience
Slide 35: First true innovation in neuromodulator formulation in over 30 years
st 1 true innovation in neuromodulator formulation in over 30 years 1 D U RATI O N F O RM U LATI O N Long-lasting treatment of effect 1st and only peptide powered formulation (PXT) 2 1 EF F I CA C Y ON SE T 98% of patients achieved none or Clinical/visible results typically mild wrinkle severity at
Slide 36: Opportunities to Enhance our Launch Success
Opportunities to Enhance our Launch Success Intended for investor audience
Slide 37: Alignment between price and product expectations is critical
MAIN TAKEAWAY BASED ON CUSTOMER FEEDBACK Alignment between price and product expectations is critical to unlocking meaningful adoption 37 Intended for investor audience
Slide 38: Success factors with price and expectation alignment
With alignment SUCCESS FACTORS between price • Proper expectation setting and expectations, ® • Alignment between price and desired outcome DAXXIFY has become top share • Favorable economics of wallet in some practices Intended for investor audience
Slide 39: High premium can lead to hurdles
HIGH PREMIUM CAN LEAD TO When there’s • Elevated consumer expectations misalignment, • More involved switch discussion hurdles to deeper • Consumer price sensitivity adoption exist • No movement expectations Intended for investor audience
Slide 40: Real-world experience and broad adoption potential
“We think we could switch over 50% of our Real-world experience confirms patients if DAXXIFY® was the unique performance profile of priced competitively DAXXIFY® and reinforces our potential ® with Botox .” to achieve broad-based adoption Plastic Surgeon, Private Practice Intended for investor audie
Slide 41: Positioning ourselves for meaningful share gain
Positioning ourselves for meaningful share gain Intended for investor audience
Slide 42: New DAXXIFY pricing
® New DAXXIFY pricing st effective September 1 OB JEC T I VES : 1. Positions 2. Makes switching 3. Gives providers 4. Allows the ® ® DAXXIFY to be to DAXXIFY flexibility to full value competitively easier for both enhance their proposition of ® ® priced to Botox injectors and economics DAXXIFY to be
Slide 43: Execution, early insights and expectations for Q3 2023
Execution, Early Insights and Expectations for Q3 2023 Based on recent roll out of EARLY INSIGHTS EX EC U TI ON st Based on 1 week of September pricing program coupled Rolled out new pricing program Strong positive feedback st on September 1 with traditional seasonality, 50% increase in number of ac
Slide 44: Launch strategy, learnings and pricing adjustments position DAXXIFY
Launch strategy, • Measured launch strategy provided valuable learnings real-world learnings • DAXXIFY’s differentiated performance profile continues and pricing to be clinically validated adjustments ® position DAXXIFY • Launch optimizations underway for future growth • Strong foundation for long-t
Slide 45: RHA Collection Overview & Progress Update
® RHA COLLECTION OVERVIEW & PROGRESS UPDATE Intended for investor audience
Slide 46: RHA Collection FDA-approved HA dermal fillers
® RHA Collection – First and only FDA-approved hyaluronic acid dermal 1 fillers for the correction of dynamic facial wrinkles and folds ™ ® ® ® RHA Redensity RHA 2 & RHA 3 RHA 4 Weightless filler that smooths Elegant softening and refined Natural volume for moderate to delicate lipstick lines smooth
Slide 47: RHA is designed to more closely resemble natural HA
® RHA is designed to more A 1-3 closely resemble natural HA • Designed for facial dynamic movement B • Created to be adaptable to facial animation for long-lasting, natural-looking results C A Intrinsic non-covalent bonds B Long hyaluronic acid chains C Low degree of BDDE modification 1. Kaufman-Jan
Slide 48: HA chain length comparison
HA LENGTH HA Gel Technology Starting Material (MW) Finished Product (MW) All HA gels have the same ® Preserved Network starting material, RHA ≥1500 kDa ~500-660 kDa ™ Technology (PNT ) technology preserves ™ 1 NASHA ≥1500 kDa ~200 kDa greater HA chain length ™ XpresHAn (OBT ) ≥1500 kDa ~100-275 kDa
Slide 49: RHA Collection offers injectors versatility
® RHA® Collection offers injectors RHA RHA ™ versatility in treating a wide range Redensity 2 of patient needs INJECTION DEPTHS BY SKU Fine-tuned finish Elegant softening for moderate to for moderate to severe perioral severe facial lines Epidermis rhytids Superficial Dermis Mid Dermis ® ® Deep Derm
Slide 50: RHA growth wins 9% market share within 3 years
® RHA growth continues, wins 9% of market share within just 3 years of launch ® REVENUE ($M) RHA Collection RA N KE D $150 9% Market Share Q2’ 23 >$250M #1 Cumulative Profitability to $100 Revenue (Q2’ 23) My Practice $123 $107 $50 RA N KE D RA N KE D $71 #1 #1 $13 $- YOY Brand Growth Relationship w
Slide 51: Account growth: strong commercial execution
ACCOUNT GROWTH Strong commercial execution >6,000 >5,000 >3,000 ~1,000 YE 2020 YE 2021 YE 2022 Q2 2023 Intended for investor audience
Slide 52: Loyalty & Practice Partnership
LOYALTY & PRACTICE PARTNERSHIP DUSTIN S. SJUTS P R ESI D EN T Intended for investor audience
Slide 53: Enhance the customer experience at every touchpoint
Enhance the customer experience at every touchpoint Our loyalty and practice Deliver a loyalty program to customers and consumers in addition to portfolio pricing partnership Continue to leverage data and digital capabilities priorities to enhance engagement Intended for investor audience
Slide 54: Customer engagement initiatives
Practice Locator Virtual & Digital in-person Marketing training Our customer engagement Data initiatives include Loyalty & Capabilities Injector Practice and insights an expanded range Events Partnership of offerings, which currently include Practice payment processing Services Payment Processing Di
Slide 55: Why payments? OPUL platform
M EM B ER S H I P S MARKET DATA Why payments? We acquired HintMD in 2020 ® and introduced the OPUL TECH & TALENT R EV EN U E platform in 2021 to accelerate G R O SS Processing Volume ($M) our digital capabilities $664 $511 $102 2020 2021 2022 Intended for investor audience
Slide 56: OPUL costs no longer align with capital allocation priorities
® Despite our progress with OPUL , the significant costs and resources required for a payments business no longer align with our capital allocation priorities Intended for investor audience
Slide 57: Exiting OPUL payments business: next steps
® • Exiting OPUL payments business by end of Q1 2024; ceasing related R&D spend while exploring strategic alternatives - 2023 projected loss from services segment ~$25M − Preliminary and estimated non-cash impairment Next steps charges from goodwill and other assets between $80M - $100M, which will
Slide 58: Well-positioned for continued growth across aesthetics
• Learnings to date validate the innovation of Well- ® DAXXIFY and our launch strategy positioned • Clear launch optimizations underway to maximize for continued share-take over time growth across • Competitive toxin and filler portfolio supported by aesthetics ® continued success of RHA Collection
Slide 59: DAXXIFY KOL Panel
® DAXXIFY KOL PANEL T ARYN M. CONWAY GENERAL MANAGER, AESTHETICS Intended for investor audience
Slide 60: Investor Day 2023 Revance Therapeutics
INVESTOR DAY 2023 REVANCE THERAPEUTICS DUSTIN S. SJUTS – P R ES ID ENT Intended for investor audience
Slide 61: Agenda
A GEND A Market Landscape Addressing the Unmet Need Commercial Launch Strategy Intended for investor audience
Slide 62: Market Landscape
MARKET LANDSCAPE Intended for investor audience
Slide 63: $2.5B U.S. market by indication
1 $2.5B U.S. Market by Indication GLOBAL MARKET OPPORTUNITY IN D IC A T IO N M AR KE T S HAR E M A R K ET SIZ E Cervical Dystonia 14% $345M 8 4% US Spasticity 27% $654M Migraine 40% $977M $2.9B +8% CAGR Overactive Bladder 6% $159M Other 13% $331M 16% E X US 1. Market size as of 2022. CAGRs represent
Slide 64: DAXXIFY for cervical dystonia provides entry into therapeutics
® DAXXIFY for cervical dystonia provides entry into significant therapeutics opportunity 1st 12 Years True innovation in Since a new botulinum toxin has over 30 years been introduced to U.S. market Intended for investor audience
Slide 65: Cervical dystonia is a painful and disabling chronic condition
Cervical dystonia is a painful and disabling chronic condition that causes the neck 1 muscles to involuntarily contract PATIENTS DIAGNOSED IN THE U.S. AGE OF ONSET TYPICALLY ~60,000 40-60s AFFECTS WOMEN 2x 85% AS OFTEN AS MEN TREATED BY BoNTs* 65 65 * Kx Movement Disorder Survey Q2,. 2019 C CO ONFI
Slide 66: Botox has never been seriously challenged in CD
2022 Share 1 ® US Botox has never been CD seriously challenged 1989 Botox® by new entrants 83% (Abbvie) Type A OTHER COMPETITORS 2000 Myobloc® ® 2% Myobloc (Supernus) Type B • 2nd line 2009 • Primarily reserved for type A Dysport® 5% non-responders (Ipsen) Type A ® ® Dysport /Xeomin 2010 Xeomin® 10%
Slide 67: CD physician community is concentrated and conservative
CD physician community is concentrated and conservative, dealing with complex conditions and treatments PRACTICE MINDSET PRACTICE FACTS O F PA TI E N TS TR E A TE D E V E R Y 9 0 D A YS 90% ~70% NO CURE CONSERVATISM * OF CD PATIENTS The best outcome is Physicians cautiously improvements in optimize
Slide 68: Conventional BoNTs do not provide durable symptom relief
Physical Limitations Loneliness Shame Loneliness For majority of CD patients, conventional BoNTs do not provide 1-3 Embarrassment durable symptom relief. Patients are left to struggle with the full Stress Shame severity of the disorder 1-3 for weeks at a time. Disability 1. Benecke R, Jost WH, Kanov
Slide 69: Addressing the Unmet Need
ADDRESSING THE UNMET NEED DAVID A. HOLLANDER, MD CHIEF MEDICAL OFFICER Intended for investor audience
Slide 70: CD patients experience return of symptoms before next treatment
Cervical dystonia patients typically experience a return of symptoms prior to their next BoNT treatment Due to product labeling restrictions and reimbursement policies, BoNT treatments are spread out 12 weeks or more, during which most CD patients experience a re-emergence of symptoms. 1 2 FIGURE 1:
Slide 71: DAXXIFY Cervical Dystonia Phase 3 trials
® Two Phase 3 trials were conducted in cervical dystonia patients, DAXXIFY Cervical including a randomized study evaluating two doses (Aspen-1) Dystonia Phase 3 Trial 1-2 and an open-label trial involving repeat dosing (Aspen-OLS). (ASPEN-1) DAXXIFY 250U (n=130) Adults with Moderate to Severe DAXXIF
Slide 72: How is efficacy assessed in CD registration studies?
E X AM P LE Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) How is efficacy assessed in CD registration studies? TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE (TWSTRS) Severity Scale (Clinician-rated): 0 – 35 Disability Scale (Patient-rated): 0 - 30 Pain Scale (Patient-rated): 0 – 2
Slide 73: Efficacy of DAXXIFY in CD
® Both 125U and 250U of DAXXIFY proved effective in providing symptom ® 1-2 Efficacy of DAXXIFY in CD relief in patients with cervical dystonia. 1 FIGURE 1: Change in TWSTRS at Weeks 4 & 6 (Primary Endpoint) 2 • p<0.0001 (125 U vs. Placebo) 2 50 45.3 • p=0.0006 (250 U vs. Placebo) 42.6 2 43.1 • p=0.
Slide 74: DAXXIFY demonstrated long-lasting duration
® DAXXIFY demonstrated long-lasting duration, with a median duration 1-4 of 20-24 weeks until significant loss of effect (~80%) 0 Placebo (n=46) ® DAXXIFY 125U (n=125) -5 ® DAXXIFY 250U (n=130) -10 -15 -20 0 4 8 12 16 20 24 28 32 36 Weeks TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale. 1
Slide 75: ASPEN-OLS individualized dose adjustments
ASPEN-OLS allowed individualized dose adjustments with Cycle 1 Cycles 2-4 (125U, 200U, 250U, or 300U) up to 4 treatment cycles at doses ® DAXXIFY 125U higher than initial 1 Phase 3 study Up to 3 additional treatments based on clinical Follow-up response ® DAXXIFY 250U 0 4 6 12 40 52 Weeks IM Injecti
Slide 76: ASPEN-OLS continued improvement with repeat dosing
ASPEN- OLS ASPEN- OLS ASPEN- OLS ASPEN- OLS The ASPEN-OLS * ASPEN-1 CYCLE 1 CYCLE 2 CYCLE 3 CYCLE 4 study demonstrated 0 continued -2 improvement with -4 repeat dosing and -6 individualized 1-2 treatment. -8 -10 -12 -12.5 -14 -15.4 -16 -17.7 -18 -17.9 -20 -19.9 -22 -24 Treatment Cycle TWSTRS, Toront
Slide 77: Dosing increased up to 300U over successive treatments
Dosing increased in some patients up to 300U over successive 1 individualized treatments 100% 90% 300U 80% 300U 70% 300U 250U 60% 250U 50% 40% 250U 30% 250U 200U 20% 125U 200U 10% 200U 125U 125U 0% Cycle 1 (n=357) Cycle 2 (n=329) Cycle 3 (n=234) Cycle 4 (n=65) 1. McAllister, P, Jinnah, HA, Evidente,
Slide 78: Treatment-related adverse events remained low
Treatment-related adverse events ASPEN-1 ASPEN-OLS remained low with repeat treatments, Treatment-Related ASPEN-1 Cycle 1 Cycle 2 Cycle 3 Cycle 4 even with Adverse Events by Cycle (n=255) (n=357) (n=329) (n=234) (n=65) increasing doses ®1-2 of DAXXIFY Any treatment-related 26.7 21.0 17.0 19.7 13.8 a
Slide 79: DAXXIFY has a strong safety profile
® DAXXIFY has a strong safety profile with a low adverse event rate, notably across important areas such as dysphagia and muscle 1-2 weakness 3 3 2.5 2.5 2.7 ng 2.7 ng 5 5 500U 500U 2 2 2.12 ng 2.12 ng 6 236U 6,8 236U 1.5 1.5 1 1 1.1ng 1.1ng 0.96 ng 0.96 ng 7 7 250U 250U 4 4 240U 240U 0.5 0.5 0.56ng
Slide 80: Dose titration to optimize outcomes
® Dose titration with DAXXIFY can be utilized to increase efficacy and duration to optimize outcomes for patients F igu r e 1 : Dose Titration to Increase Efficacy F i g u re 2: Dose Titration to Increase Duration TWSTRS, Toronto Western Spasmodic Torticollis Rating Scale TWSTRS, Toronto Western Spa
Slide 81: Time of retreatment cycle
TIME OF RETREATMENT CYCLE - 1 Approved label provides 35% physicians flexibility in 30% 32% optimizing individualized treatment plans 25% 1 23% • Recommended dose of 125 to 250 units. 20% • Label contains data from repeat dose open 15% label trial, 28 (7.8%) subjects received one 13% treatment, 95 (
Slide 82: Long duration may allow fewer treatments per year
® The long duration of DAXXIFY may allow fewer treatments per year as well as more days of symptom relief 1-2 • Patients want to be treated as their symptoms re-emerge and before they return to baseline. 3 • For example, patients requested retreatment in ASPEN with ~40-50% peak efficacy remaining. F
Slide 83: Commercial Launch Strategy
COMMERCIAL LAUNCH STRATEGY ROB E. BANCROFT GENERAL MANAGER, THERAPEUTICS Intended for investor audience
Slide 84: DAXXIFY delivers for all stakeholders
P H Y SIC IAN Confidence to optimize treatment outcomes for patients ® DAXXIFY P AY ER Opportunity for category cost delivers for all management 3 stakeholders P ATIENT Potential for more good days Intended for investor audience
Slide 85: Physicians: measured launch strategy
Physicians Measured launch strategy designed to optimize patient outcomes and ensure smooth practice integration MID-YEAR 2024 SEPT 1, 2023 2-3 injection cycles Optimized dose, duration Operational best practices PREVU EARLY C O MME R C IAL SEPT 15, 2023 EXPERIENCE PROGRAM LAU N C H • 11 physicians
Slide 86: Payers: managing medical benefit drug spend
Payers Striving to manage medical benefit drug spend 1 BoNTs are #12 most costly medical benefit drug category 65% 60% 30% of commercial of CD treatment utilization mgmt (UM) payers cover by is covered by within the commercial category; commercial channel 35% cover by payers brand Trending Up 5% 15%
Slide 87: DAXXIFY economics: annual drug costs vs market leader
® DAXXIFY Economics Annual drug costs favorable vs. the market leader DIRECT VIAL COST ANNUALIZED COMPARISON ® ® vs BOTOX D A X XI F Y Graph represents first two quarters of WAC-based reimbursement. ASP-based reimbursement expected to begin Q2 2024 List price for 100U vials $7,608 $7,608 $8,000 ® BO
Slide 88: DAXXIFY resonating with payers
® DAXXIFY Resonating with Payers Unique clinical profile, attractive economics ”No denying we need to revisit our ® UM strategy in light of DAXXIFY .” TOP REGIONAL PLAN WITH >1.5M LIVES BoNT step edit in place for years, covers by brand Potential cost UP TO savings per year ”The clinical efficacy an
Slide 89: Patients: the most important stakeholder
The most important stakeholder Patients INNOVATIVE PRODUCT Opportunity for more good days BETTER ECONOMICS Reduced co-insurance LONG DURATION Potentially fewer injections IInt ntend ended ed f for or i inv nves est tor or a aud udiienc ence e
Slide 90: Aspiration: BoNT of choice for CD
Aspiration: BoNT of Choice for CD Unique product, strong economic value, efficient strategy MUST WIN BATTLES Infrastructure Leverage PrevU to • Sales accelerate broader • Field Reimbursement adoption at launch • Medical Affairs • Ntl Acct Directors TARGETED GO-TO-MARKET Optimized, scalable switching
Slide 91: Future Growth Opportunities
INVESTOR DAY 2023 FUTURE GROWTH OPPORTUNITIES DUSTIN S. SJUTS – P R ES ID ENT Intended for investor audience
Slide 92: Multiple paths to growth beyond U.S. aesthetics
Multiple paths to growth beyond ® DAXXIFY Strategic Therapeutics International Partnerships Pipeline U.S. aesthetics Expansion Expansion Intended for investor audience
Slide 93: DAXXIFY supply chain investments support future growth
® DAXXIFY supply chain investments support future growth—creating opportunity for higher capacity and lower cost over time 2010 2017 2021 2023 2025 WHOLLY-OWNED CMO SIGNED CMO SIGNED CMO APPROVAL ANTICIPATED U.S.-BASED AJINOMOTO PCI PHARMA AJINOMOTO CMO APPROVAL MANUFACTURING BIOSCIENCES BIOSCIENCES
Slide 94: Significant OUS neuromodulator market
EU C H INA CA N A DA Significant OUS neuromodulator market totaling $2.6B Key countries and regions represent majority of opportunity A U STR A LI A B R A ZIL Market size as of 2022. Decision Resources Group Aesthetics Injectables Botulinum Toxin Reports- 2023. Intended for investor audience
Slide 95: Partnership with Fosun Pharma
Partnership with Fosun Pharma P R OVID ES REGULATORY MILESTONES potential entry into CHINA NMPA BLA ACCEPTANCES: 2024 1st ® DAXXIFY for glabellar lines – April 2023 AN TI C I P AT E D 2 A PPR OVA L S ® DAXXIFY for cervical dystonia - July 2023 international market for DAXXIFY®, China, a 1 $740M mark
Slide 96: Partnership with Viatris: biosimilar to BOTOX
Partnership with Viatris - ® Biosimilar to BOTOX P R OG R ESS P R OVID ES potential access to ü Secured agreement with FDA on ® path to BOTOX biosimilar Overactive bladder Cervical dystonia Detrusor overactivity Axillary hyperhidrosis ® ü Analytic characterization of BOTOX Pediatric detrusor overact
Slide 97: Unlocking near-term and long-term therapeutics opportunity
Unlocking our near-term and long-term opportunity in therapeutics IN D IC A T IO N U S M A R K ET SIZ E Phase 3 – FDA Approved CD Commercial Launch Cervical Dystonia $345M Adult Upper Limb Spasticity – Spasticity $654M End of Phase 2 Meeting Complete Migraine $977M Additional Data Generation Opportu
Slide 98: Future revenue streams represent upside to current valuation
Future potential revenue streams represent significant upside to current valuation ® D AXXI F Y STRATEGIC PARTNERSHIPS POTENTIAL 1 U.S. THERAPEUTICS MARKET FOSUN PHARMA VIATRIS CE R VI CA L UP T O UP T O DY ST O N IA SP A ST IC IT Y $2.0B $223M $225M M IG R A IN E MI L ES T O N E PA Y MEN T S MI L E
Slide 99: Financial Review
INVESTOR DAY 2023 FINANCIAL REVIEW TOBIN C. SCHILKE – CHIEF FINANCIAL OFFICER Intended for investor audience
Slide 100: Product revenue
PRODUC T REVENUE ($ M) $200 $172M Solid track $150 $49 record of $11 $100 $1 $123 financial results $107 $50 $71 supported by innovative product portfolio and commercial strategy $13 $- 2020 2021 2022 TTM Q2'23 RHA® COLLECTION DAXXIFY® Intended for investor audience
Slide 101: Revenue guidance plan
Revenue guidance plan 2024 2023 2022 2021 ® ® st ® st ® DAXXIFY full 1 full year of DAXXIFY 1 full year of RHA DAXXIFY Approval and commercial launch launch Collection launch Q4 PrevU program Sales force expansion Expects to provide to 150 product revenue guidance in the first half of 2024 Intended
Slide 102: Long-term supply chain strategy supports gross margin
Long-term • Scale and leverage from U.S.-based CMOs Ajinomoto Biopharma (2023) supply chain and PCI Pharma (2025) strategy supports • Hybrid supply chain optimizes CapEx ® U.S. DAXXIFY and gross margins • Supports competitive COGs and Adjusted Gross margin profile for OUS expansion * Margin of >80%
Slide 103: 2023 opex guidance
Pr i or Cur r e nt GAAP OPEX RANGE $460M - $480M $545M - $585M Revised N ON -GAAP OPEX RANGE $320M - $340M $315M - $335M 2023 OPEX Guidance N ON -GAAP R&D EXPENSE $80M - $90M $75M - $85M Revised GAAP OPEX range reflects anticipated impairment charges from the company’s payment processing platform. I
Slide 104: Capital allocation priorities
Capital allocation priorities support continued growth across aesthetics and therapeutics AE S TH E TI C S D AXXI FY® SUPPLY CHAIN GRO W TH TH E RAP E U TI C S L A U NC H Intended for investor audience
Slide 105: Growing operating leverage
Growing operating NO N -GAAP OPEX AS % OF REVENUE 800% leverage with: 700% 600% nd ® • 2 aesthetics product launch (DAXXIFY ) 500% ® • DAXXIFY therapeutics launch 400% • Focused sales and marketing investments 300% 200% • Supply chain efficiencies 100% • Maximizing current capabilities: 0% Q4'20 Q1'
Slide 106: Nashville Experience Center
Nashville Experience Center CASE STUDY Trainings/customer events per year 50-60 Annual cost savings compared to hosting externally $5-7M Payback 1 Year IInt ntend ended ed f for or i inv nves est tor or a aud udiienc ence e
Slide 107: Funded to 2025
AS OF Q2 '23 Funded to $320M 2025 In cash, cash equivalents, short-term cash flow EX P EC T P OS I TI V E investments ADJ U S T E D E B I T DA* I N 2 02 5 break-even +$50 M In notes funded in August 2023 from Note Purchase Agreement *Adjusted EBITDA is defined as earnings before interest, taxes, dep
Slide 108: Near-term and long-term financial positioning
NEA R - TE R M LONG - TE R M • Continued disciplined capital allocation • Cash position of $319.7 million at end of Q2’23, coupled with additional − Streamlining operations by exiting $50M in notes funds Revance to ® Executing OPUL payments business positive Adjusted EBITDA in 2025 − Frees up ~$20M/
Slide 109: Closing Remarks
INVESTOR DAY 2023 CLOSING REMARKS MARK J. FOLEY – CHIEF EXECUTIVE OFFICER Intended for investor audience
Slide 110: Closing: focused on long-term value creation
• Leading innovation across neuromodulators and Focused on dermal fillers long-term • Demonstrated ability to execute with RHA collection value creation product launch and, with adjusted DAXXIFY® strategy, positioned for meaningful share growth • Robust potential in therapeutics franchise • Addition
Slide 111: Q&A
INVESTOR DAY 2023 Q&A Intended for investor audience
Slide 112: Trademarks notice
INVESTOR DAY 2023 All trademarks are property of their respective owners